Related Experiment Video
Updated: Sep 14, 2026

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
Published on: September 23, 2021
Assessing persistent antitumor immunity induced by tumor derived extracellular vesicle hydrogel vaccination without
Xiaoya Wang1, Daxiu Deng1, Yixi He2
1Department of Pathology, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, China.
Abstract:
Personalized cancer vaccines show great promise in targeting tumors with immunity; however, obstacles to their widespread use in clinical practice remain, including difficulties in identifying neoantigens, slow antigen clearance, and inadequate removal of tumor cells expressing the antigen. Here, we present a hydrogel vaccination platform based on tumor-derived extracellular vesicles (TDEVs) that may produce long-lasting, personalized immune responses against tumors, all without the need for time-consuming neoantigen screening. After subcutaneous injection, the hydrogel scaffold formed an in situ antigen reservoir, enabling the recruitment and activation of dendritic cells (DCs) and the sustained release of TDEVs and immunomodulatory components. Activated dendritic cells (DCs) migrated to draining lymph nodes. They induced strong tumor specific CD8+ T-cell responses by maintaining an antigen-rich milieu for an extended period, thereby facilitating effective DC maturation and antigen presentation. The hydrogel vaccination elicited long-lasting antitumor immunity and substantially slowed tumor growth across multiple mouse tumor models. Notably, this strategy has strong translational promise, as customized vaccinations made from extracellular vesicles extracted directly from tumors successfully prevented tumor recurrence after surgery. From a mechanistic standpoint, the hydrogel scaffold helped preserve antigens, enhanced immune activation, and facilitated the formation of long lasting immunological memory. Taken together, our results show that hydrogel vaccination based on TDEV is a flexible and powerful immunotherapeutic platform capable of producing strong, long-lasting protection against tumors. One potential way to create next-gen tailored cancer immunotherapies is to use this approach, which avoids the requirement for significant neoantigen research without sacrificing therapeutic effectiveness.
More Related Videos
11:07Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination
Published on: April 29, 2015
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Related Concept Videos
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...